Galderma's nemolizumab shows sustained itch relief in children with atopic dermatitis in Phase II study

Galderma announced Phase II results showing nemolizumab improved itch, sleep disturbance and quality of life in children with moderate-to-severe atopic dermatitis. Benefits in children aged 2 to 11 lasted through one year of treatment; nemolizumab was well tolerated, with no new safety signals. Results will be presented at the 2026 Pediatric Dermatology Research Alliance Annual Conference. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galderma Group AG published the original content used to generate this news brief via (Ref. ID: 20261014705800) on October 15, 2026, and is solely responsible for the information contained therein. (C)